Crossject
Research Crossject (ALCJ) on Bullrun: market cap EUR 76.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALCJ
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Market capEUR 76.87M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 10.37M
- Free cash flow-EUR 10.85M
Valuation Snapshot
latest market cap is EUR 76.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 10.37M | -EUR 10.85M | n/a | n/a | EUR 5.08M | EUR 19.82M | -EUR 4.87M |
| FY2024 | EUR 0 | -EUR 12.80M | -EUR 11.48M | n/a | -0.28 | EUR 7.04M | EUR 18.35M | -EUR 2.67M |
| FY2023 | EUR 145.00K | -EUR 8.64M | -EUR 12.60M | -4231.0% | -0.23 | EUR 2.30M | EUR 18.93M | -EUR 5.27M |
| FY2022 | EUR 954.00K | -EUR 11.16M | -EUR 11.86M | -126.4% | -0.29 | EUR 7.77M | EUR 14.13M | EUR 2.69M |
| FY2021 | n/a | n/a | n/a | n/a | -0.4 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 76.87M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Crossject's market cap?
Crossject's market capitalization is EUR 76.87M.
What does Crossject do?
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures.